HCS Pharma is revolutionising drug discovery with a unique 3D cell technology, BIOMIMESYS®
HCS PHARMA has raised $2.2M in total funding. The most recent round was Initial Coin Offering. The last funding was announced in March 2022.
HCS PHARMA's investors include The Global Emerging Markets Group, Eurasante.
HCS PHARMA is headquartered in Loos, France.
HCS Pharma is revolutionising drug discovery with a unique 3D cell technology, BIOMIMESYS®
HCS PHARMA is at the Initial Coin Offering stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HCS PHARMA — Funding & Investors." VCBacked, March 1, 2022, https://www.vcbacked.co/company/hcs-pharma. Accessed September 30, 2026.
VCBacked. (2022). HCS PHARMA — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/hcs-pharma
{{cite web |title=HCS PHARMA — Funding & Investors |url=https://www.vcbacked.co/company/hcs-pharma |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated